Navigation Links
Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
Date:12/9/2010

BETHESDA, Md., Dec. 9, 2010 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 2 diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested (2.5, 5.0, and 7.5 g TID), with the 2.5 and 5.0 g doses producing similar responses to one another, and the 7.5 g dose producing a greater response.

In addition, by the end of the six-month trial, the 7.5 g dose reduced serum triglycerides vs. the 2.5 g dose by -42 mg/dl from a mean of 180 mg/dl in the Evaluable Efficacy (EE) population. The reduction in serum triglycerides became statistically significant in the Intent-To-Treat (ITT) population at three months of treatment (-31 mg/dl, p=0.03) and the reduction essentially held steady at the six-month end-of-study visit (-29 mg/dl).

In the single-blind study designed to establish the minimum dose capable of causing a beneficial effect, three different doses of D-tagatose were administered to patients orally with meals TID. The comparator was the 2.5 g dose. The study was designed with a minimum of 34 patients in each of the three groups for a total of 102 evaluable patients. The primary endpoint for the study was reduction in HbA1c after six months of treatment. In the minimum dose range, D-tagatose produced a -0.3% reduction in HbA1c in the 7.5 g dose group vs. the 2.5 g dose group in the EE population, from a mean randomization HbA1c of 7.4%. The reduction of the 7.5 g dose was 0.2% more than the 2.5 g dose in the ITT population.

Unlike
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Spherix Signs Research Contract With a Leading Global Contract Research Organization to Investigate Role of D-tagatose in Lowering Triglycerides
2. Spherix to Hold Business Update Conference Call December 9, 2010 at 4:30 p.m. Eastern Time
3. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
4. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
5. Spherix Announces Second Quarter 2010 Financial Results
6. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
7. Spherix Announces Results of Annual Shareholders Meeting
8. Spherix Incorporated Announces Annual Shareholders Meeting Date
9. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
10. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing ... The National Eye Institute (NEI) at the National Institutes ... SBIR grant to develop a drug-eluting intraocular lens (IOL) ... cause of vision loss in people over age 40 ... Dr. Ken Mandell, LayerBio’s Founder and CEO, "There is ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 In contrast ... of LEDs with various colors, Valoya uses proprietary LED ... This offers best possible uniformity which is critical in ... and high spectral accuracy throughout its lifetime which is ... LED tubes. , "The investment cost was clearly ...
(Date:12/19/2014)... Dec. 18, 2014 Egenix, Inc. is pleased to ... Chairman of the Board, to succeed Donald Fresne ; ... will continue as a member of the Board.  In recognition ... to the company over almost twenty years, the Board designated ... of Directors has established a Search Committee to find a ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Germany, May 12 , - ... , The number of employees in ... 2006 and 2008. In this same period, the number of,companies ... These,figures were presented today by Dr. Klaus-Dieter Juszak, Chairman of ...
... treatment of Spinal Muscular Atrophy SOUTH PLAINFIELD, N.J. and ... and the Spinal Muscular Atrophy (SMA) Foundation today announced ... SMA Foundation will provide up to $8.5 million in ... of the collaboration to fund a series of research ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... has successfully completed patient enrolment in its multi-centre Phase ... REOLYSIN(R) in patients with various sarcomas that have metastasized ... been enrolled in the trial. , "We are extremely ...
Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 3
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... from the King Juan Carlos University (URJC) have carried ... looked at whether spiders were more tolerant of human ... suffer the consequences of changes to their landscape just ... number of spider species is negatively affected by the ...
... researchers from Tel-Aviv University show that predator-prey interactions between ... amphibians are much more complex than expected. The study ... Keys . , "Amphibians are typical insect predators and ... particular. The recently filmed successful attacks of the beetles ...
... from a late-night infomercial: It can twist and bend ... help you fend off disease! But in this ... including the U.S. Department of Energy,s Lawrence Berkeley National ... protein-making machine, the ribosome, at key stages of its ...
Cached Biology News:Spiders suffer from human impact 2Small insects attacks and kill amphibians much bigger than themselves 2Atomic-scale structures of ribosome could help improve antibiotics 2Atomic-scale structures of ribosome could help improve antibiotics 3
Request Info...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
Contact us for more information...
Biology Products: